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dioxin's toxicity has reignited controversy
regarding safe exposure levels for dioxin and
prompted the reassessment by the EPA. As
part of these efforts, scientists at NIEHS
developed mechanistic models to challenge
the dioxin threshold hypothesis.
At the heart ofthe dioxin controversy is
a proposed hypothesis that toxic effects of
dioxin are receptor mediated, and at suffi-
ciently low exposure to dioxin (i.e., a thresh-
old), too few receptors would be occupied to
produce a significant biological consequence.
Researchers Christopher Portier and Michael
Kohn ofthe Laboratory ofQuantitative and
Computational Biology, in collaboration
with the Laboratory of Biochemical Risk
Analysis and the Biostatistics Department of
the German Cancer Research Center, used
data on the effects ofdioxin, including tissue
concentrations, changes in expression ofliver
proteins, modification ofplasma membrane
epidermal growth factor, interactions with
estrogens, cellular proliferation, and carcino-
genesis, to create a comprehensive mechanis-
tically based model ofdioxin's effects.
Portierand Kohn found that although the
classical receptor-mediated models theoreti-
cally allowed for both nonlinear behavior
that mimics a threshold and linearity at low
doses, these models failed to predict a non-
linear relationship at low doses. The models
predict that binding of dioxin to the Ah
receptor follows linear kinetics at low doses,
and induction of the Ah receptor by the
dioxin-Ah receptor complex does not alter
this curvature. Binding of dioxin to other
liver proteins does not seem to significantly
affect the dose-response curve for expression
of any of the proteins modeled. Not only
were the NIEHS models unable to detect
any nonlinearity in cell kin-
etics, they also indicated that
dioxin potentially produces
premalignant lesions in the
liver.
Because changes in gene
expression do not necessarily
predict toxicity, current stud-
ies are attempting to develop
dose-response models to
determine if the toxic effects
of dioxin exhibit linear or
nonlinear behavior. For ex-
ample, Portier and Kohn
have undertaken a theoretical
analysis of the impact of re-
ceptor-based models on the
shape and magnitude of tu-
mor incidence rates.
EPA Reevaluation of Dioxin's
Risks
In 1991, then EPA administrator William
Reilly initiated a reevaluation of dioxin's
risks. George Lucier and Christopher
Portier have been involved in this reevalua-
Michael Kohn-modeling effects
of dioxin
tion in a number of ways. Lucier and
Michael Gallo (EOHSI) co-chair the com-
mittee that prepared the dose-response
models chapter, the corner-
stone of the reevaluation.
Portier played a key role in
the development of biologi-
cally based dose-response
models for dioxin's effects.
Lucier also prepared the
chapter on animal carcino-
genicity. The dose-response
models and animal carcino-
genicity chapters received
favorable reviews from the
EPA Peer Review process in
September 1992. The Sci-
entific Advisory Board will
review the background pa-
pers and the risk characteriza-
tion in late 1993.
Species Differences in
Butadiene Carcinogenesis
1,3-Butadiene, a gaseous hydrocarbon used
in the production of synthetic rubber and
other resins, is a carcinogen in rodents and is
associated with leukemia and lymphoma in
humans. Mice develop tumors at lower
exposures to butadiene than rats. Recent
studies have shown that mice have a higher
capacity to oxidize butadiene to 1,2-epoxy-
3-butene, a mutagenic and carcinogenic
compound, than either rats or humans.
Some investigators have concluded that
species differences in tumor development are
due to differences in metabolic activation of
butadiene and detoxification of expoxide
intermediates.
To validate this conclusion, two NIEHS
scientists, Michael Kohn and
Ronald Melnick, constructed
physiologically based pharma-
cokinetic models ofthe distri-
bution and clearance of in-
haled butadiene in mice, rats,
and humans. In contrast to
the conclusions of earlier in-
vestigators, the models predict
that species differences in the
uptake of butadiene and the
blood concentration ofepoxy-
butene are much more sensi-
tive to the physiological para-
meters (e.g., ventilation rate
and cardiac output) than to
the biochemical parameters.
In addition, the model pre-
dicts that, because ofthese physiological dif-
ferences, butadiene accumulates in the fat of
humans, but not mice, on repeated expo-
sure. According to the model, butadiene
released from fat during the periods between
exposures continues to be converted into
epoxybutene, adding to the carcinogenic
risk.
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In a recent editorial in Science, it was
stated that after exposure to 10 ppm butadi-
ene in the ambient air, blood epoxybutene
levels are 590 times higher in
mice than in monkeys. Yet,
in Kohn and Melnick's mod-
els, mice produce only 5.5
times as much epoxybutene
as humans at exposures that
result in equivalent amounts
of butadiene absorbed into
the body. Risk assessments of
inhaled carcinogens are nor-
mally performed on the basis
of internal dose rather than
on the basis of atmospheric
concentration. Inhalation
studies can lead to different
implications relevant to hu-
man risk depending on the
manner in which the results
are reported.
Computed epoxybutene concentrations,
by themselves, were found not to correlate
with tumor incidence in mice and rats. Rats
exposed to 1000 ppm butadiene generate
about twice the concentration of epoxy-
butene in lung as mice exposed to 60 ppm.
Yet mice develop lung tumors under those
conditions and rats do not. Kohn and
Melnick conclude that other biochemical
processes (e.g., formation of DNA adducts,
efficiency of DNA repair) not included in
their models are more important determi-
nants ofthe differential response ofthe two
species than the concentration of the puta-
tive carcinogen.
Risk Assessment Seminar
Series
As an adjunct to its initiatives in risk assess-
ment, NIEHS is hosting a seminar series
featuring prominent scientists in the risk
assessment field. The first seminar was June
8, with Christopher Portier, chief of the
NIEHS Laboratory of Quantitative and
Computational Biology. Other speakers in
the series will include David P. Rall, inter-
nationally recognized environmental health
researcher and retired director of NIEHS;
Joe Rodricks of Environ, a Washington,
DC firm; John Graham ofthe Harvard In-
stitute ofRisk Assessment; William Farland
and John Vandenberg of U.S. EPA; Henry
Falk of CDC; Ellen Silbergeld of the
University of Maryland at Baltimore and
the Environmental Defense Fund; Leslie
Staynor of NIOSH; Gil Omenn of the
University of Washington; and Roger
McClellan of the Chemical Industry In-
stitute ofToxicology.
The series is designed to allow profes-
sionals in risk assessment to discuss critical
issues. For information on the series con-
tact George Lucier, (919) 541-3802.
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